1. Home
  2. MNPR vs NC Comparison

MNPR vs NC Comparison

Compare MNPR & NC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNPR
  • NC
  • Stock Information
  • Founded
  • MNPR 2014
  • NC 1913
  • Country
  • MNPR United States
  • NC United States
  • Employees
  • MNPR N/A
  • NC N/A
  • Industry
  • MNPR Biotechnology: Pharmaceutical Preparations
  • NC Coal Mining
  • Sector
  • MNPR Health Care
  • NC Energy
  • Exchange
  • MNPR Nasdaq
  • NC Nasdaq
  • Market Cap
  • MNPR 249.5M
  • NC 247.6M
  • IPO Year
  • MNPR 2019
  • NC N/A
  • Fundamental
  • Price
  • MNPR $31.73
  • NC $35.86
  • Analyst Decision
  • MNPR Strong Buy
  • NC
  • Analyst Count
  • MNPR 5
  • NC 0
  • Target Price
  • MNPR $59.50
  • NC N/A
  • AVG Volume (30 Days)
  • MNPR 18.2K
  • NC 8.4K
  • Earning Date
  • MNPR 05-13-2025
  • NC 04-30-2025
  • Dividend Yield
  • MNPR N/A
  • NC 2.82%
  • EPS Growth
  • MNPR N/A
  • NC N/A
  • EPS
  • MNPR N/A
  • NC 4.61
  • Revenue
  • MNPR N/A
  • NC $249,990,000.00
  • Revenue This Year
  • MNPR N/A
  • NC N/A
  • Revenue Next Year
  • MNPR N/A
  • NC N/A
  • P/E Ratio
  • MNPR N/A
  • NC $7.79
  • Revenue Growth
  • MNPR N/A
  • NC 14.71
  • 52 Week Low
  • MNPR $1.72
  • NC $25.19
  • 52 Week High
  • MNPR $54.30
  • NC $39.65
  • Technical
  • Relative Strength Index (RSI)
  • MNPR 37.28
  • NC 51.93
  • Support Level
  • MNPR $34.02
  • NC $35.31
  • Resistance Level
  • MNPR $36.82
  • NC $36.70
  • Average True Range (ATR)
  • MNPR 3.54
  • NC 0.99
  • MACD
  • MNPR -0.71
  • NC 0.02
  • Stochastic Oscillator
  • MNPR 27.91
  • NC 52.93

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

About NC NACCO Industries Inc.

NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments that are coal mining, North American mining (NA mining), and minerals management. The majority of its revenue is from the coal mining segment. This segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The NA mining segment provides value-add contract mining and services for producers. Minerals management generates income from royalty-based leases by acquiring and promoting oil, gas, and coal mineral interests. The company is diversifying beyond coal mining due to political and economic pressures associated with carbon emissions.

Share on Social Networks: